Serotyping and antibiotic susceptibility patterns of *Vibrio* and *Shigella* isolates from diarrheal patients visiting a Tropical and Infectious Diseases Hospital in central Nepal

Sujan Maharjan¹, Binod Rayamajhee²,³*, Anima Shreshtha⁴ and Jyoti Acharya⁵

**Abstract**

**Background:** Diarrheal diseases are the major infectious disease in developing countries like Nepal. Lack of proper sanitation and antimicrobial resistance gained by microbes have challenged to address diarrheal diseases in resource-limited countries. Early diagnosis of disease and proper antibiotic treatment can significantly reduce the disease burden. This study was designed to determine the recent antimicrobial susceptibility pattern of *Vibrio cholerae* and *Shigella* spp. to assure the proper antibiotic treatment. Stool specimens were processed following microbiological protocol and identified by biochemical and serological tests recommended by the Clinical Laboratory Standard Institute.

**Results:** Out of total 640 analyzed stool samples, 50 were culture positive, among them 29 were *Shigella* spp. (64.4%) and 21 were *V. cholerae* (46.6%). All *V. cholerae* strains belonged to the serogroup O1 and serovar Ogawa. Among the *Shigella* spp., *Shigella flexneri* 17 (59%) topped the list of serotype followed by *Shigella sonnei* 8 (28%), *Shigella dysenteriae* 3 (10%) and *Shigella boydii* 1 (3%) respectively. All the *V. cholerae* isolates (100%) were sensitive to cefotaxime while 71% were sensitive to tetracycline but 100 and 90.4% were resistance to co-trimoxazole and nalidixic acid respectively. *Shigella* isolates were mostly susceptible to cefotaxime (97%) while ciprofloxacin (48%) and ofloxacin (55%) were less effective drugs.

**Conclusions:** These results on the prevalence of enteropathogens and their antibiotic resistance pattern may help to guide accurate choice of therapy in clinical setting. Hence, development of evidence based National Guidelines for the treatment of diarrhea is needed.

**Keywords:** Diarrheal disease, Antimicrobial resistance, Serotype
via contaminated water and food, diarrheal diseases become more active during the monsoon season [3, 4]. 

*Shigella* is one of the leading causes of bacterial diarrhea in Nepal and contains four species *flexleri*, *sonnei*, *dysenteriae*, and *boydii*. In the Mid and Far Western parts of the country *Shigella flexleri* has been the predominant isolate with 43.07% [5]. The prevalence of *Shigella* species causing an acute diarrhea in children under 5 years of age in Kathmandu valley is 4.6% [6]. Similarly, cholera is a secretory diarrhea disease that causes excessive fluid secretion which can result from bacterial enterotoxin (cholera toxin) of *Vibrio cholerae* strains. More than 150 serogroups of *V. cholerae* have been confirmed but the toxigenic serogroup O1 of *V. cholerae* is the cardinal causative serogroup of several outbreaks since long time ago [7]. All the isolates of *V. cholerae* were serogroup O1 of the classical biotype where subtype was Ogawa [8]. During cholera outbreak in Far-Western part of Nepal in 2013, all the isolates were *V. cholerae* having prevalence of 47.06% [9].

Antimicrobial resistance (AMR) is one of the greatest challenges to the public health locally and globally and has gained particular concern in the developing world. Herein Nepal, inappropriate use of antibiotics is very common which creates an environment where drug-resistant microbes flourish very rapidly. Additionally, the resistance of enteric bacteria to antibiotics has been increasing very sharply both in developed and developing communities [10]. The rate of AMR in our health setting is alarming and the preparation for its future calamities is almost zero. AMR has seen even to new antimicrobial drugs and is very commonly observed in bacteria like *V. cholerae*, *Shigella*, *Salmonella*, and *Staphylococcus aureus* [11]. In context of Nepal, underuse, misuse and overuse of antibiotics without health care professional advice, availability of antibiotics even in local groceries, use of antibiotics in farm and field, sharing of antibiotics with family and friends are very common which accelerate the development of antimicrobial resistance [12]. Thus, the main objective of this study was to identify *Shigella* spp., *V. cholerae* and monitor the changing antimicrobial susceptibility pattern in Nepal.

**Methods**

This study was carried out in Sukraraj Tropical and Infectious Disease Hospital, from June 2014 to December 2014. A total of 650 stool samples were processed from the patients who had been consulted with the clinician were included as the study subject. The stool samples were transferred to microbiology laboratory and processed as soon as possible according to the standard laboratory methods. In this study, patients have remained in hospital for longer than 3 days and/or in prior antibiotic use were kept in exclusion criteria.

For the isolation of *V. cholerae*, a loopful of fresh watery stool was inoculated on alkaline peptone water (APW) (pH 8.6) in a volume of 1:10. In case of swab it was dipped into the alkaline peptone water tube directly and incubated aerobically for 6 h at 37 °C. After incubation, precaution was taken to avoid shaking of the enrichment culture which may disturb the growth at the surface of the broth while solid and semi-solid stool samples were directly inoculated on xylose lysine deoxycholate agar (XLD) and MacConkey agar (MA) then incubated at 37 °C for 24 h. Similarly, after 6 h the APW inoculated samples were streaked on thiosulfate citrate bile salts sucrose (TCBS) and MA then incubated at 37 °C for 24 h. After proper incubation period, the TCBS plates were observed for the presence of yellow button shaped sucrose fermenting colonies while XLD plates were observed for the pink red colonies of 1–2 mm diameter with no black center and late lactose fermenting colonies on MA. Then, the pathogenic organism was further sub-cultured on nutrient agar for isolation of pure colonies at 37 °C for 24 h and appropriate biochemical tests (catalase, oxidase, urease, sulfide indole motility, triple sugar iron, citrate) were performed [13]. The *V. cholerae* was confirmed as sucrose fermenting yellow colonies on TCBS, late lactose fermenting colonies on MA, oxidase positive, catalase positive, urease negative, glucose and sucrose fermentative, maltose non-fermentative, citrate positive, indole positive, methyl red negative, Voges–Proskauer negative, hydrogen sulfide (H2S) negative, and in triple sugar iron agar tube acid/acid with no gas production (identification of *V. cholerae* CDC, 2012). The pink colonies from XLD and late lactose fermenting colonies from MA were tested for urease production, citrate utilization, indole production, motility, acid and gas production with sugar utilization. *Shigella* spp. were confirmed based on biochemical results along with oxidase and urease negative tests (identification of *Shigella* spp. Public Health England, 2015). While serological identification was done for the *Shigella* spp. for the identification of specific species using the polyvalent antisera A–D (*Shigella* Antisera) and *V. cholerae* (polyvalent O1, Inaba, Ogawa and Hikojima type monovalent antisera) by slide agglutination method with the use of specific antisera manufactured by Denka Seiken Co. Ltd., Japan. Slide agglutination was performed on a glass slide by emulsifying the growth in a small drop of physiological saline and mixed thoroughly by tilting back and forth for 30 s. Small drop of antiserum was added to the respective suspension. The suspension and antiserum were mixed well and tilted back and forth to observe for visible agglutination. One drop of physiological saline and the growth emulsion was used as a negative control and to observe for auto-agglutination (Denka Seiken Co. Ltd., Japan). Details of the serotyping
by slide agglutination method is included in Additional file 1: Appendix S1.

Antibiotic susceptibility test of the isolated and identified strains was performed by modified Kirby Bauer disc diffusion method; a standard dilution of the test isolate was prepared by matching it with 0.5 McFarland turbidity standards and was uniformly swabbed over the Mueller Hinton agar (MHA) medium. Then antibiotic discs (Hi-media, Mumbai, India): ampicillin (10 µg), cotrimoxazole (1.25 µg/23.5 µg), nalidixic acid (30 µg), cefotaxime (30 µg), chloramphenicol (30 µg), ciprofloxacin (5 µg), ofloxacin (5 µg), and tetracycline (30 µg) were placed on the medium and incubated at 37 °C for 24 h according to the isolated organism. After incubation period the zone of inhibition were measured and results were interpreted as per the guidelines given by the Clinical Laboratory Standard Institute (CLSI) [14].

Results
From total of 650 stool samples processed, 50 samples were found to be positive for enteric bacterial pathogens of which 21 (3%) were *V. cholerae* and 29 (5%) were *Shigella* spp. where total positive case was 7.7% (Fig. 1).

Serotyping results showed that all the strains of *V. cholerae* agglutinate polyvalent O1 antisera hence all *V. cholerae* belonged to serogroup O1 and serotype Ogawa while non of them were neither Inaba nor Hikojima serotype. Out of 29 *Shigella* species isolated, *S. flexneri* was the highest with 17 (59%), followed by *Shigella sonnei* 8 (28%), *Shigella dysenteriae* 3 (10%) where *Shigella boydii* was the least isolated with 1 (3%) (Table 1). Among 650 samples, the highest positive cases of gastroenteritis was seen in ward patients (in-patients) of 82%, followed by out-patients with 18% and no positive cases was seen in patients living with human immuno deficiency virus (PLHIV) (Table 2). There was no significant difference in occurrence between gastroenteritis cases and type of the patients (P > 0.05). The patients of age group 15–30 years were mostly affected by both cholera (52%) and shigellosis (38%) (Fig. 2). Among 50 positive cases, 28 (56%) were isolated from male while 22

---

**Table 1 Result of serotyping of isolated *Shigella* species**

| Shigella serogroup | Shigella species       | Number of cases | Percentage % |
|--------------------|-----------------------|----------------|--------------|
| Polyvalent A       | *Shigella dysenteriae*| 3              | 10           |
| Polyvalent B       | *Shigella flexneri*   | 17             | 59           |
| Polyvalent C       | *Shigella boydii*     | 1              | 3            |
| Polyvalent D       | *Shigella sonnei*     | 8              | 28           |

---

**Table 2 Patients wise distribution of gastroenteritis**

| Patient type | Result | Total | p value |
|--------------|--------|-------|---------|
| Negative cases | Positive cases | | |
| Out patients | 170 | 9 (18%) | 179 | 0.12 |
| In patients | 414 | 41 (82%) | 455 | |
| PLHIV | 16 | 0 (0%) | 16 | |
| Total | 600 | 50 | 650 | |

---

**Fig. 1** Distribution of the positive cases in total samples. From total of 650 stool samples analyzed, 50 samples were found to be positive for enteric bacterial pathogens of which 29 (5%) were *Shigella* spp. and 21 (3%) were *Vibrio cholerae* where total positive case was 7.7%.

**Fig. 2** Age wise distribution of gastroenteritis. The patients of age group 15–30 years were mostly affected by both cholera (52%) and shigellosis (38%).
(44%) were isolated from female patients (Table 3) where there was no significant differences in between growth of the pathogen and gender of patients (P > 0.05).

The distribution of bacterial pathogens of gastroenteritis showed increment in rainy season and sharp decrement in winter. The peak value of cholera positive cases were seen in the month of August with a steady curve graph. The highest number of shigellosis was seen in November with a zig zag pattern of graph plot (Fig. 3). All the isolated V. cholerae were found to be sensitive to cefotaxime (CTX), while 71% were sensitive and 29% were intermediately sensitive to tetracycline (TET). All the strains were completely resistant to cotrimoxazole (COT) and 90% were resistant to nalidixic acid (NA) (Table 4). Almost all the Shigella isolates in this study were susceptible to cefotaxime (97%) except one isolate which was found to be resistant to this drug. The isolated Shigella spp. were mostly found to be resistant to nalidixic acid (NA) (76%), ampicillin (AMP) (58%), and cotrimoxazole (55%). Ciprofloxacin (CIP) and ofloxacin (OF) which are used as a drug of choice were found to be 48 and 55% sensitive for Shigella spp. whereas resistance was 52 and 41% for ciprofloxacin and ofloxacin respectively (Table 5).

Statistical analysis
Chi square test was used to evaluate apparent differences for significance at 95% confidence level. Association of bacterial isolates with different variables were tested. Results were considered significant if P value was less than 0.05 and insignificant if more than 0.05. Statistical Package for the Social Sciences (SPSS version 21.0) was used for the Chi square test.

Discussion
This study helps to understand the prevalence of enteric pathogens which is related to the public health concern in developing countries like Nepal and the need of antibiopic susceptibility assay for proper treatment and to control the emergence of resistant organisms.

In this study, 650 stool samples were processed for the isolation of V. cholerae and Shigella spp. and their antimicrobial sensitivity test was performed. Out of these, 50 positive cases were found, of which 21 cases were V. cholerae and 29 cases were Shigella spp., resulting in the total positive case of 7.7%. The causes of diarrhea in patients without positive bacterial culture might be parasitic infections, bacteria other than V. cholerae and Shigella spp., or foodborne infection and intoxication. The result had a similar prevalence with the study carried out by Ansari et al. [6]. Moreover, Kansakar et al. [15] have observed 15% culture positivity for bacterial enteropathogens from stool samples. Since, the prevalence of enteric disease varies from place to place while proper sanitation and hygiene of the people affect the occurrence of the disease. Bacterial pathogens could have been missed in the single stool sample processed so, second sample for stool culture should be made available to rule out the negative culture [16]. Also antibiotics are often consumed in Nepal without consulting the physicians, so administration of antibiotics prior to collection of stool samples may be one of the causes of 7.7% growth positivity.

The prevalence rate of cholera was 3.2% and is comparable to findings of Kansakar et al. [15] and Shah et al. [17]. The prevalence rate of shigellosis was 4.5% which is comparable to Shah et al. [17], Kansakar et al. [15] and Ansari et al. [6]. The highest number of positive cases were seen in the inpatients (hospitalized) or ward patients of 41 (82%) and 9 (18%) were from outpatients while no pathogenic bacteria were isolated from PLHIV patients. There was no statistical association between the type of patients and the gastroenteritis cases (P > 0.05). Out of 50 positive cases, 56% were male and 44% were female. Thus, there is sufficient evidence to say that there was no association between sex and the incidence of the disease.

| Gender | Result | Total | P value |
|--------|--------|-------|---------|
|        | Negative | Positive |         |
| Male   | 274     | 28    | 302     | 0.15    |
| Female | 326     | 22    | 348     |         |
| Total  | 600     | 50    | 650     |         |

Table 3 Gender wise distribution of gastroenteritis

Fig. 3 Month wise distribution of gastroenteritis from June 2014 to Dec 2014. The distribution of bacterial pathogens of gastroenteritis showed increment in rainy season and sharp decrement in winter. The peak value of cholera positive cases were seen in the month of August with a steady curve graph. The highest number of shigellosis was seen in November with a zig zag pattern of graph plot.
In this study male patients were slightly more infected than female and age wise distribution of gastroenteritis cases showed that the cases were high in the age group 15–30 which is then followed by 30–45 and 60–75. There was no significant difference in occurrence of gastroenteritis cases and the age group (P > 0.05). The cause of high number of male patient with age group 15–30 may be due to the fact that the people of this age group are of working age group and the unhygienic food and water may have caused the infection of enteric diseases. Also highest number of cholera cases was observed during the rainy season and peak value was seen in August whereas shigellosis was seen almost all over the study period with highest number of cases in November (31%). In Nepal, rainy season starts from early June and lasts till September. The arrival of monsoon brings up the number of acute diarrheal diseases and cholera is a major diarrheal disease among them. During the study period all the isolated strains of *Vibrio* (21) were *V. cholerae* serogroup O1 serotype Ogawa. In recent years, Ogawa is predominant serotype of *V. cholerae* O1 during epidemics season. *V. cholerae* O1 serotype Ogawa and of biotype El Tor was the only serotype isolated during the outbreak of diarrhea in Kavre, Nepal in 2004 [18] and same serotype was isolated during 2008–2009 in a laboratory based surveillance study conducted by Karki et al. [19].

Among 29 *Shigella* spp. isolated, *S. flexneri* was the most predominant species with 17 (59%), then next were *S. sonnei* 8 (28%), *S. dysenteriae* 3 (10%) where *S. boydii* was the least isolated with 1 (3%). From this study, it is observed that *S. flexneri* was the common species responsible for causing dysentery followed by *S. sonnei*, *S. dysenteriae* and *S. boydii*. The similar finding was obtained in the study conducted by Kansakar et al. [15] in which *S. flexneri* was the most prevalent species (43.2%) but the second highest species was found *S. dysenteriae* (41.5%), followed by *S. sonnei* (7.6%) and *S. boydii* (7.6%).

In this study, antibiotic susceptibility test (AST) for the isolated and identified species was performed by modified Kirby Bauer disc diffusion method for seven different antibiotic discs. The AST result shows that all the isolates of *V. cholerae* were found to be sensitive to cefotaxime (CTX), while 71% were sensitive and 29% were intermediately sensitive to tetracycline (TET). The isolated *V. cholerae* were found to be 100, 90, and 67% resistant to cotrimoxazole, nalidixic acid, and ampicillin in decreasing order. Similar findings were reported during *V. cholerae* O1 Ogawa strains isolated in 2008 in Kathmandu by Karki et al. [19]. This study showed that tetracycline may still be used as the drug of choice in case of severe cholera cases as none of the isolated showed resistant to this drug. But still the antibiotic susceptibility test should be performed prior to drug prescription which reduce the antibiotic resistance and disease burden.

Almost all the *Shigella* isolates in this study were susceptible to cefotaxime (97%) except one isolate which

---

**Table 4 Antibiotic susceptibility pattern of *Vibrio cholerae***

| Total positive cases | Antibiotics | Sensitive (%) | Intermediate (%) | Resistant (%) |
|---------------------|-------------|---------------|------------------|--------------|
|                     | Ampicillin  | –             | 33               | 67           |
|                     | Cotrimoxazole | –            | –                | 100          |
|                     | Nalidixic acid | –           | 10               | 90           |
| 21                  | Cefotaxime   | 100           | –                | –            |
|                     | Chloramphenicol | 57         | 33               | 10           |
|                     | Ciprofloxacin | 81           | 19               | –            |
|                     | Tetracycline  | 71            | 29               | –            |

**Table 5 Antibiotic susceptibility pattern of *Shigella* spp.**

| Total positive cases | Antibiotics | Sensitive (%) | Intermediate (%) | Resistant (%) |
|---------------------|-------------|---------------|------------------|--------------|
|                     | Ampicillin  | 21            | 21               | 58           |
|                     | Cotrimoxazole | 41          | 4                | 55           |
|                     | Nalidixic acid | 17          | 7                | 76           |
| 29                  | Cefotaxime   | 97            | –                | 3            |
|                     | Chloramphenicol | 86         | 7                | 7            |
|                     | Ciprofloxacin | 48           | –                | 52           |
|                     | Ofloxacin    | 55            | 4                | 41           |
was found to be resistant to this drug. Ciprofloxacin and ofloxacin which are used as a drug of choice were found to be 48 and 55% sensitive for this organism respectively whereas resistance was 52 and 41% for ciprofloxacin and ofloxacin respectively. Ciprofloxacin is considered as the drug of choice for all kind of patients with bloody diarrhoea but resistance has seen in many parts of the world. Cefotaxime and other third generation cephalosporins are currently in use for the treatment of multi-drug resistant (MDR) species of *Shigella* while azithromycin is used as an alternative drug for the treatment of young adults. The prescription of these alternative drugs like ceftriaxone and azithromycin is restricted because of high rate of resistance in resource limited countries like Nepal. Generally alternative drugs are used when the isolated strains of *Shigella* are resistant to ciprofloxacin [20].

**Conclusions**

This study shows that the isolated bacterial enteric pathogens were *V. cholerae* O1 serovar Ogawa and *Shigella* spp. which includes *S. flexneri*, *S. sonnie*, *S. dysenteriae*, and *S. boydii*. Tetracycline and ciprofloxacin showed an adequate effectiveness against the isolated strains of *V. cholerae*. In this study the isolated *Shigella* spp. were mostly resistant to nalidixic acid followed by ampicillin, cotrimoxazole, ciprofloxacin, and ofloxacin while cefotaxime was found to be most effective drug. So, regular laboratory monitoring of antimicrobial susceptibility pattern is becoming cardinal in order to choose the accurate drug and in designing evidence-based National Guidelines for the treatment of diarrheal patients in developing regions.

**Additional file**

Additional file 1: Appendix S1. Determining serotypes of *Vibrio* and *Shigella* species.

**Abbreviations**

AST: antibiotic susceptibility test; WHO: World Health Organization; NCID: National Center for Infectious Diseases; CDC: Centers for Disease Control and Prevention; USAID: United States Agency for International Development; CLSI: Clinical Laboratory Standard Institute; PLHIV: patients living with human immunodeficiency virus; APW: alkaline peptone water; GE: gastroenteritis; MHA: Mueller–Hinton agar; µg: micro gram.

**Authors’ contributions**

First authors: SM is primary author who designed the study methodology, performed laboratory investigations. BR is corresponding author who edited and revised the manuscript, helped to design the study and laboratory investigations. Second authors: AS and JA helped for design the study, analysis of results, proof reading of article and manage necessary arrangements during laboratory investigations. All authors approved the final manuscript before submission to the BMC Research Notes. All authors read and approved the final manuscript.

**Author details**

1. St. Xavier’s College (Tribhuvan University), Maitighar, Kathmandu, Nepal.
2. Kathmandu Research Institute for Biological Sciences (KRIBS), 19533, Lalitpur, Nepal. 3 Department of Microbiology, National College (Tribhuvan University), Khusibu, Kathmandu, Nepal. 4 Tri-Chandra Multiple College (Tribhuvan University), Ghanaghar, Kathmandu, Nepal. 5 National Public Health Laboratory, Government of Nepal, Ministry of Health Services, Teku, Kathmandu, Nepal.

**Acknowledgements**

We would like to acknowledge STIDH director Dr. Kedar Prasad Sentury, senior laboratory staff of STIDH Mr. Ram Prasad Shreshtha for guiding the study and Hi Media Pvt. Ltd.—who provided antibiotic discs for the antimicrobial susceptibility tests. This work has been presented as poster at Second International Conference on Infectious Diseases and Nanomedicine 2015, December 15–18, 2015, Kathmandu, Nepal.

**Competing interests**

The authors declare that they have no competing interests.

**Availability of data and materials**

The datasets used and analysed during this study are available in excel sheets which can be obtained from the corresponding author on reasonable request.

**Consent for publication**

Not applicable.

**Ethics and consent to participate**

The ethical approval for this study was taken from the Institutional Ethical Review Board (IERB) of Sukraraj Tropical and Infectious Diseases Hospital, Kathmandu before sample collection. The issued letter of IERB can be presented on request. Written consent was taken from all the patients in local language. This manuscript does not contain any individual human or animal data or tissue.

**Funding**

Not applicable.

**Publisher’s Note**

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

**Received**: 24 October 2016  **Accepted**: 21 November 2017

**Published online**: 28 November 2017

**References**

1. World Health Organization. Fact sheets of diarrheal disease. http://www.who.int/mediacentre/factsheets/fs330/en. Accessed July 2016.
2. Sharma AK, Jha N, Ramachandran VG, Shaffir M, Deb M, Kannan AT, Pauldel IS, Yadav BK. Descriptive epidemiology of a gastroenteritis out break in Sunsari district, Nepal. J Nepal Med Assoc. 2002;41(143):383–7.
3. Pandey BD, Thapa LB, Sherchand JB, Rimal N, Bhattarai A, Morita K. Etiology of diarrhoea among adult patients during the early monsoon period in Kathmandu, Nepal. Jpn J Trop Med Hyg. 2002;30(2):133–7.
4. Maharjan R, Lekhak B, Shrestha CD, Sheeha J. Detection of enteric bacterial pathogens (*Vibrio cholerae* and *Escherichia coli*) in childhood diarrhoeal cases. Sci World. 2007;5(5):23–6.
5. Khan S, Singh P, Ansari M, Asthana A. Isolation of *Shigella* species and their resistance patterns to a panel of fifteen antibiotics in mid and far western region of Nepal. Asian Pac J Trop Dis. 2014;4(1):30–4.
6. Ansari S, Sherchand JB, Parajuli K, Mishra SK, Dahal RK, Shrestha S, Tandukar S, Pokhrel BM. Bacterial etiology of acute diarrhea in children under five years of age. J Nepal Health Res Counc. 2012;10(22):218–23.
7. World Health Organization, Centers for Disease Control and Prevention. Laboratory methods for the diagnosis of epidemic dysentery and cholera. Atlanta: World Health Organization, Centers for Disease Control and Prevention; 1999.
8. Shrestha UT, Adhikari N, Maharjan R, Banjara MR, Rijal KR, Basnyat SR, Agrawal VP. Multidrug resistant *Vibrio cholerae* O1 from clinical and environmental samples in Kathmandu city. BMC Infect Dis. 2015;15(1):104. https://doi.org/10.1186/s12879-015-0844-9.
9. Bhandari GP, Bhusal CL. Cholera outbreak in far-western region of Nepal. J Nepal Health Res Counc. 2013;11(23):6–8.
10. Alleyne G, Claeson M, Evans DB, Jha P, Mills A, Musgrove P. Disease control priorities in developing countries. Washington, DC: World Bank; 2006.
11. Sack RB, Rahman M, Yunus M, Khan EH. Antimicrobial resistance in organisms causing diarrheal disease. Clin Infect Dis. 1997;24(Suppl 1):S102–5.
12. Malla S, Dumre SP, Shaktiya G, Kansakar P, Rai B, Hussain A, Nair GB, Albert MJ, Sack D, Baker S, Rahman M. The challenges and successes of implementing a sustainable antimicrobial resistance surveillance programme in Nepal. BMC Public Health. 2014;14(1):269. https://doi.org/10.1186/1471-2458-14-269.
13. Forbes BA, Sahm DF, Weissfeld AS, Bailey SS. Diagnostic microbiology. 12th ed. St. Louis: Mosby Elsevier; 2007. p. 778–81.
14. Clinical and Laboratory Standards Institute (CLSI), Performance standards for antimicrobial susceptibility testing, in twenty-third informational supplement. Wayne: Clinical and Laboratory Standards Institute; 2013. CLSI Document M100–S23.
15. Kansakar P, Baral P, Malla S, Ghimire GR. Antimicrobial susceptibilities of enteric bacterial pathogens isolated in Kathmandu, Nepal, during 2002–2004. J Infect Dev Ctries. 2011;5(03):163–8. https://doi.org/10.3855/jidc.1016.
16. Humphries RM, Linscott AJ. Laboratory diagnosis of bacterial gastroenteritis. Clin Microbiol Rev. 2015;28(1):3–31. https://doi.org/10.1128/CMR.00073-14.
17. Shah BK, Sharma S, Shaktiya G, Upadhayay BP. Cholera, Shigellosis and Salmonellosis incidence among the people of some Districts of Nepal. Nepal J Sci Technol. 2013;13(1):165–72. https://doi.org/10.3126/njst.v13i1.7455.
18. Tamang MD, Sharma N, Makaju RK, Samra AN, Kaju R, Nepali N, Mishra SK. An outbreak of El Tor cholera in Kavre district, Nepal. Kathmandu Univ Med J. 2005;3(2):138–42.
19. Karki R, Bhatta DR, Malla S, Dumre SP. Cholera incidence among patients with diarrhea visiting National Public Health Laboratory, Nepal. Jpn J Infect Dis. 2010;63(3):185–7.
20. World Health Organization. Guidelines for the control of shigellosis, including epidemics due to Shigella dysenteriae type 1. Geneva: World Health Organization; 2005.